Zobrazeno 1 - 10
of 17
pro vyhledávání: '"the UTOPIA study investigators"'
Autor:
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Akira Kurozumi, Masahiro Hatazaki, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Ken Kato, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-15 (2023)
Abstract Background This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an appare
Externí odkaz:
https://doaj.org/article/8358aaeab0374c86b4c5f65e4528a3a5
Autor:
Naoto Katakami, Tomoya Mita, Norikazu Maeda, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, The UTOPIA Study Investigators
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Since sodium-glucose cotransporter 2 (SGLT2) inhibitors have a pleiotropic antiatherogenic effect, they are expected to attenuate the progression of atherosclerosis. However, whether SGLT2 inhibitors affect the tissue characterist
Externí odkaz:
https://doaj.org/article/3a8b480ea0564dee94f26cff1747b912
Autor:
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-16 (2020)
Abstract Background This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascul
Externí odkaz:
https://doaj.org/article/b6c9bc1a1d3f4cccabeef7301d3b3b75
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Utopia Study Investigators, Yutaka Umayahara, Takeshi Osonoi, Hiroki Yokoyama, Tsunehiko Yamamoto, Mamiko Tsugawa, Toshihiko Shiraiwa, Naoto Katakami, Nobuichi Kuribayashi, Satoru Sumitani, Kayoko Ryomoto, Hidenori Yoshii, Keisuke Kosugi, Kazuhisa Maeda, Keiichi Torimoto, Iichiro Shimomura, Yosuke Okada, Hideki Taki, Tadashi Nakamura, Hirotaka Watada, Isao Hayashi, Tomoya Mita, Hideaki Kaneto, Yasunori Sato, Satoshi Kawashima, Kentaro Ohtoshi, Tetsuyuki Yasuda
Publikováno v:
Diabetes Therapy
Introduction Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with ty
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, On behalf of the UTOPIA study investigators
Publikováno v:
Cardiovascular Diabetology
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
BackgroundTofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP). This study evaluated
Publikováno v:
Diabetes. 69
Background: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disea
Autor:
Tomoya Mita, Utopia Study Investigators, Kazuhisa Maeda, Keiichi Torimoto, Naoto Katakami, Tetsuyuki Yasuda, Takeshi Osonoi, Yutaka Umayahara, Tsunehiko Yamamoto, Toshihiko Shiraiwa, Kayoko Ryomoto, Hirotaka Watada, Iichiro Shimomura, Hidenori Yoshii, Mamiko Tsugawa, Tadashi Nakamura, Isao Hayashi, Keisuke Kosugi, Hideaki Kaneto, Nobuichi Kuribayashi, Satoru Sumitani, Satoshi Kawashima, Kentaro Ohtoshi, Yasunori Sato, Yosuke Okada, Hideki Taki, Hiroki Yokoyama
Publikováno v:
SSRN Electronic Journal.
Background: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disea